Nascent Biotech Inc. NBIO
We take great care to ensure that the data presented and summarized in this overview for Nascent Biotech Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in NBIO
Top Purchases
Top Sells
About NBIO
Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. In addition, the company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. Nascent Biotech, Inc. is based in Vero Beach, Florida.
Insider Transactions at NBIO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2024
|
Sean Carrick President & CEO |
BUY
Other acquisition or disposition
|
Direct |
192,000
+0.82%
|
$0
$0.09 P/Share
|
|
Jun 30
2024
|
Lowell Thomas Holden CFO |
BUY
Other acquisition or disposition
|
Direct |
96,000
+0.95%
|
$0
$0.09 P/Share
|
|
Jun 30
2024
|
Douglas John Karas |
BUY
Other acquisition or disposition
|
Direct |
50,000
+2.67%
|
$0
$0.1 P/Share
|
|
Mar 31
2024
|
Douglas John Karas |
BUY
Other acquisition or disposition
|
Direct |
27,100
+1.51%
|
$0
$0.18 P/Share
|
|
Mar 31
2024
|
Sean Carrick President & CEO |
BUY
Other acquisition or disposition
|
Direct |
225,000
+0.97%
|
$0
$0.18 P/Share
|
|
Mar 31
2024
|
Lowell Thomas Holden CFO |
BUY
Other acquisition or disposition
|
Direct |
112,500
+1.12%
|
$0
$0.18 P/Share
|
|
Dec 29
2023
|
Douglas John Karas |
BUY
Other acquisition or disposition
|
Direct |
28,935
+1.63%
|
$0
$0.18 P/Share
|
|
Dec 29
2023
|
Lowell Thomas Holden CFO |
BUY
Other acquisition or disposition
|
Direct |
119,650
+1.21%
|
$0
$0.17 P/Share
|
|
Dec 29
2023
|
Sean Carrick President & CEO |
BUY
Other acquisition or disposition
|
Direct |
239,300
+1.04%
|
$0
$0.17 P/Share
|
|
Sep 29
2023
|
Sean Carrick President & CEO |
BUY
Other acquisition or disposition
|
Direct |
2,772,600
+10.98%
|
$0
$0.12 P/Share
|
|
Sep 29
2023
|
Lowell Thomas Holden CFO |
BUY
Other acquisition or disposition
|
Direct |
1,386,300
+12.53%
|
$0
$0.12 P/Share
|
|
Sep 29
2023
|
Douglas John Karas |
BUY
Other acquisition or disposition
|
Direct |
39,750
+2.26%
|
$0
$0.12 P/Share
|
|
Jun 29
2023
|
Sean Carrick President & CEO |
SELL
Bona fide gift
|
Direct |
960,000
-4.65%
|
$0
$0.05 P/Share
|
|
Jun 29
2023
|
Lowell Thomas Holden CFO |
SELL
Bona fide gift
|
Direct |
700,000
-7.79%
|
$0
$0.05 P/Share
|
|
Jun 07
2023
|
Lowell Thomas Holden CFO |
BUY
Open market or private purchase
|
Direct |
130,000
+1.52%
|
$0
$0.04 P/Share
|
|
Mar 31
2023
|
Sean Carrick President & CEO |
BUY
Other acquisition or disposition
|
Direct |
1,167,000
+5.72%
|
$0
$0.06 P/Share
|
|
Mar 31
2023
|
Lowell Thomas Holden CFO |
BUY
Other acquisition or disposition
|
Direct |
581,000
+6.56%
|
$0
$0.06 P/Share
|
|
Mar 31
2023
|
Douglas John Karas |
BUY
Other acquisition or disposition
|
Direct |
89,285
+5.36%
|
$0
$0.06 P/Share
|
|
Feb 09
2023
|
Lowell Thomas Holden CFO |
SELL
Bona fide gift
|
Direct |
700,000
-8.24%
|
$0
$0.12 P/Share
|
|
Jan 27
2023
|
Lowell Thomas Holden CFO |
BUY
Open market or private purchase
|
Direct |
40,000
+0.24%
|
$0
$0.14 P/Share
|